Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Actuate Therapeutics, Inc. Common stock

A biopharmaceutical company developing treatments for hard-to-treat cancers, aiming to give patients the opportunity to live longer and better through a self-described best-in-class agent.

	Mar '24	Jun '24	Sep '24
revenue
cost of revenue
gross profit
selling and marketing expenses
general and administrative expenses	912.82K -	1.06M 16.41%	1.64M 53.94%
selling general and administrative expenses	912.82K -	1.06M 16.41%	1.64M 53.94%
research and development expenses	6.86M -	4.37M 36.26%	3.76M 14.08%
other expenses
cost and expenses	7.77M -	5.44M 30.07%	5.39M 0.78%
operating expenses	7.77M -	5.44M 30.07%	5.39M 0.78%
interest expense	5.08K -	5.08K 0%	3.49K 31.26%
ebitda	-8.29M -	-6.57M 20.79%	-5.97M 9.13%
operating income	-7.77M -	-5.44M 30.07%	-5.39M 0.78%
depreciation and amortization	-517.73K -	-1.13M 118.59%	-574.57K 49.23%
total other income expenses net	-522.80K -	-1.14M 117.44%	-578.06K 49.15%
income before tax	-8.30M -	-6.57M 20.78%	-5.97M 9.15%
income tax expense
net income	-8.30M -	-6.57M 20.78%	-5.97M 9.15%
weighted average shs out	15.49M -	19.11M 23.38%	10.77M 43.63%
weighted average shs out dil	15.49M -	19.11M 23.38%	10.77M 43.63%
eps	-0.54 -	-0.34 37.04%	-0.55 61.76%
epsdiluted	-0.54 -	-0.34 37.04%	-0.55 61.76%

ACTU

COM:ACTUATETHERAPEUTICS

Actuate Therapeutics

Last Close

8.98

22/11 21:00

Market Cap

195.32M

Beta: -

Volume Today

30.74K

Avg: -

Preview